BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boudewijns S, Bol KF, Schreibelt G, Westdorp H, Textor JC, van Rossum MM, Scharenborg NM, de Boer AJ, van de Rakt MW, Pots JM, van Oorschot TG, Duiveman-de Boer T, Olde Nordkamp MA, van Meeteren WS, van der Graaf WT, Bonenkamp JJ, de Wilt JH, Aarntzen EH, Punt CJ, Gerritsen WR, Figdor CG, de Vries IJ. Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. Oncoimmunology 2016;5:e1191732. [PMID: 27622047 DOI: 10.1080/2162402X.2016.1191732] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Bloemendal M, Bol KF, Boudewijns S, Gorris MA, de Wilt JH, Croockewit SA, van Rossum MM, de Goede AL, Petry K, Koornstra RH, Figdor C, Gerritsen WR, Schreibelt G, de Vries IJM. Immunological responses to adjuvant vaccination with combined CD1c + myeloid and plasmacytoid dendritic cells in stage III melanoma patients. OncoImmunology 2022;11:2015113. [DOI: 10.1080/2162402x.2021.2015113] [Reference Citation Analysis]
2 Galli F, Aguilera JV, Palermo B, Markovic SN, Nisticò P, Signore A. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. J Exp Clin Cancer Res 2020;39:89. [PMID: 32423420 DOI: 10.1186/s13046-020-01586-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
3 Raaijmakers TK, Ansems M. Microenvironmental derived factors modulating dendritic cell function and vaccine efficacy: the effect of prostanoid receptor and nuclear receptor ligands. Cancer Immunol Immunother 2018;67:1789-96. [PMID: 29998375 DOI: 10.1007/s00262-018-2205-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 He Y, Guo Y, Chen J, Hu X, Li X, Kong Y, Zhang X, Zhou X, Liu L, Hou J. Multiple Antigen Stimulating Cellular Therapy (MASCT) For Hepatocellular Carcinoma After Curative Treatment: A Retrospective Study. J Cancer 2018;9:1385-93. [PMID: 29721048 DOI: 10.7150/jca.23725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Mennens SFB, Bolomini-Vittori M, Weiden J, Joosten B, Cambi A, van den Dries K. Substrate stiffness influences phenotype and function of human antigen-presenting dendritic cells. Sci Rep 2017;7:17511. [PMID: 29235514 DOI: 10.1038/s41598-017-17787-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
6 Fournier C, Martin F, Zitvogel L, Kroemer G, Galluzzi L, Apetoh L. Trial Watch: Adoptively transferred cells for anticancer immunotherapy. Oncoimmunology 2017;6:e1363139. [PMID: 29147628 DOI: 10.1080/2162402X.2017.1363139] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
7 Garg AD, Vara Perez M, Schaaf M, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology 2017;6:e1328341. [PMID: 28811970 DOI: 10.1080/2162402X.2017.1328341] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 10.0] [Reference Citation Analysis]
8 Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 2017;6:e1386829. [PMID: 29209573 DOI: 10.1080/2162402X.2017.1386829] [Cited by in Crossref: 124] [Cited by in F6Publishing: 77] [Article Influence: 24.8] [Reference Citation Analysis]
9 Boudewijns S, Bloemendal M, de Haas N, Westdorp H, Bol KF, Schreibelt G, Aarntzen EHJG, Lesterhuis WJ, Gorris MAJ, Croockewit A, van der Woude LL, van Rossum MM, Welzen M, de Goede A, Hato SV, van der Graaf WTA, Punt CJA, Koornstra RHT, Gerritsen WR, Figdor CG, de Vries IJM. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer Immunol Immunother 2020;69:477-88. [PMID: 31980913 DOI: 10.1007/s00262-019-02466-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]